IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that Pierre Labb, IMVs Chief Financial Officer will present at the Cowen and Company 39th Annual Health Care Conference, which will be held March 11-13, 2019 in Boston, MA.
IMVs presentation details include:
- Date: Wednesday, March 13, 2019
- Time: 9:20 “ 9:50 a.m. ET
- Location: Salon C, 4th Floor at The Marriott Copley Hotel, Boston, MA
There will be a live webcast of IMVs presentation accessible thru the IMV website at: http://wsw.com/webcast/cowen52/imv/ and the presentation will then be archived for 90 days afterwards. A copy of the presentation will also be available in the Events & Presentations section of IMVs website: www.imv-inc.com.
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Companys proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMVs lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at www.imv-inc.com.
Marc Jasmin, IMV Senior Director,
Investor Relations and Communications
O: (902) 492-1819 ext : 1042
(514) 617-9481 E: [email protected]
Andrea Cohen, Sam Brown Inc.
209-7163 E: [email protected]